# Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

Study · id `cardio:ct-nct04686643` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04686643](<https://clinicaltrials.gov/study/NCT04686643>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04686643

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 306 participants.

## Technical summary

Registry record NCT04686643. Randomized; double masking; primary purpose treatment. Start 2021-02-01 (anticipated); primary completion 2022-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 306 participants (planned count; ClinicalTrials.gov record NCT04686643, source copy `cardio:ctgov-nct04686643-2020-12-29`, retrieved 2026-10-26)
- Planned start: 2021-02-01 (anticipated) (ClinicalTrials.gov record NCT04686643, source copy `cardio:ctgov-nct04686643-2020-12-29`, retrieved 2026-10-26)
- Primary completion: 2022-02-01 (anticipated) (ClinicalTrials.gov record NCT04686643, source copy `cardio:ctgov-nct04686643-2020-12-29`, retrieved 2026-10-26)
- Completion: 2022-05-01 (anticipated) (ClinicalTrials.gov record NCT04686643, source copy `cardio:ctgov-nct04686643-2020-12-29`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04686643-2020-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension
- Condition: Hypertension
- Intervention (Drug): AGSAVI
- Intervention (Drug): AGLS
- Lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd (`cardio:org-ahn-gook-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 2afba1dca4ffdfad4a0daed57eab9297039ecafc1723561bd8c40235acb796d3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
